ctDNA and MRI Parameters in Head and Neck Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood draw, MRI.
- Who it may be relevant to
- Registry conditions: Head and Neck Neoplasms, Carcinoma, Squamous. Basic parameters: 19 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
ctDNA and MR Imaging Parameters as Possible Biomarkers in Primary Radiochemotherapy of Head and Neck Squamous Cell Carcinomas
Overview
Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study. In addition to standard of care treatment patients will undergo addiational blood draws and MR imaging studies. Circulating cell free tumor DNA will be analysed in the blood samples. BIological data, imaging data and clinical data (such as patient and tumor characteristics, oncologic outcome, side effects) will be analysed in a biomathematical modelling approach.
Interventions
- Other Blood draw, MRI
Blood draw, MRI
Primary outcome measures
- percentage of patients with 50% decrease in ctDNA [Time frame: 7 weeks after start of radiotherapy]
Secondary outcome measures (2)
- Completion of all planned MR imagings and blood tests [Time frame: through study completion, an average of 7 weeks]
- Decrease of tumor volume [Time frame: 7 weeks after start of radiotherapy]
Eligibility criteria
Inclusion criteria
- Squamous cell carcinoma head and neck
- Planned primary platinum based radiochemotherapy
- ECOG 0-2
Exclusion criteria
- Palliative therapy intent
- Not MR eligible
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06215612 · 1452/2023